The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
Although the FDA has already approved the regimen in this indication after seeing its impact on progression-free survival, the latest data speaks to its impact on survival.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
The researchers aimed to develop a test that could help clinicians determine whether a patient would respond to therapy, before the onset of treatment.
The cancer immunotherapy regimen and companion diagnostic test will be available in Europe for patients with triple-negative breast cancer who express PD-L1.
Researchers studied isolated CTCs along with real-world patient data and found that patients with blood-borne HER2 mutations may respond to anti-HER2 treatment.
After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.
Progression-free survival times were comparable for EGFR-mutated non-small cell lung cancer cases treated with a combination of erlotinib and bevacizumab treatment or erlotinib.
